Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats

1996 ◽  
Vol 39 (3) ◽  
pp. 205-211 ◽  
Author(s):  
T. Takechi ◽  
Koushi Nakano ◽  
Junji Uchida ◽  
Akira Mita ◽  
Kisako Toko ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Models ◽  
Experimental Tumor ◽  
Intestinal Toxicity ◽  
New Formulation

The Comparative Study of Antitumor Activity and Safety of the Novel Protein-targeted Actinomycin Drugs Delivery in Experimental Tumor Models of Mice.

2016 ◽  
Vol 3 (3) ◽  
pp. 188-199 ◽  
Author(s):  
B. I. Kruglyi ◽  
E. D. Nikolskaya ◽  
E. S. Severin ◽  
G. G. Barsegyan ◽  
N. G. Yabbarov ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Comparative Study ◽  
The Novel ◽  
Tumor Models ◽  
Experimental Tumor ◽  
The Comparative Study ◽  
Novel Protein

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

2012 ◽  
Vol 18 (14) ◽  
pp. 3846-3855 ◽  
Author(s):  
Harvey Wong ◽  
Edna F. Choo ◽  
Bruno Alicke ◽  
Xiao Ding ◽  
Hank La ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Clinical Response ◽  
Cytotoxic Agents ◽  
Tumor Models ◽  
Subcutaneous Tumor

Abstract A217: The HSP90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor models.

2011 ◽  
Author(s):  
Tomoko Smyth ◽  
Thomas Van Looy ◽  
Jayne Curry ◽  
Agnieszka Wozniak ◽  
Ana Rodriguez-Lopez ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Gastrointestinal Stromal Tumor ◽  
Hsp90 Inhibitor ◽  
Stromal Tumor ◽  
Tumor Models ◽  
Imatinib Resistant

Abstract 328: Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models

2016 ◽  
Author(s):  
Ketil André Camilio ◽  
Baldur Sveinbjørnsson ◽  
Sylvie Maubant ◽  
Guillaume Serin ◽  
Jean-François Mirjolet ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Models ◽  
Syngeneic Tumor

Abstract 2669: Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models

2017 ◽  
Author(s):  
Francis Bichat ◽  
Sylvie Maubant ◽  
Jean-François Mirjolet ◽  
Philippe Slos ◽  
Arthur M. Krieg ◽  
...  
Keyword(s):  
Antitumor Activity ◽  
Tumor Models ◽  
Immune Modulators ◽  
Tlr9 Agonist ◽  
Syngeneic Tumor

Abstract 5783: Strong antitumor activity of ASN007, an oral ERK1/2 inhibitor, in PDX tumor models with MAP kinase pathway alterations including KRAS mutations

2018 ◽  
Author(s):  
Sanjeeva P. Reddy ◽  
Niranjan S. Rao ◽  
Roger A. Smith ◽  
Scott K. Thompson ◽  
Sarper Toker
Keyword(s):  
Antitumor Activity ◽  
Map Kinase ◽  
Tumor Models ◽  
Kras Mutations ◽  
Map Kinase Pathway ◽  
Strong Antitumor Activity ◽  
Kinase Pathway

scholarly journals Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

2017 ◽  
Vol 7 (11) ◽  
pp. 1306-1319 ◽  
Author(s):  
Melinda Mata ◽  
Claudia Gerken ◽  
Phuong Nguyen ◽  
Giedre Krenciute ◽  
David M. Spencer ◽  
...  
Keyword(s):  
T Cells ◽  
Antitumor Activity ◽  
Solid Tumor ◽  
Tumor Models ◽  
Car T Cells ◽  
Car T ◽  
Inducible Activation
Sign in / Sign up

Export Citation Format

Share Document